Overview

MK0431 Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-040)

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
0
Participant gender:
All
Summary
This is a clinical study to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Sitagliptin Phosphate
Criteria
Inclusion Criteria:

- Patients have Type 2 Diabetes Mellitus and have laboratory results that are within the
values established by the study such as an Hemoglobin A1c (HbA1c) >=7.5% and <=11% and
a Fasting Plasma Glucose (FPG) >=130 mg/dL and <=280 mg/dL

Exclusion Criteria :

- Patients have Type 1 Diabetes Mellitus or required insulin therapy within the past 12
months